Illinois 2023-2024 Regular Session

Illinois Senate Bill SB3414

Introduced
2/8/24  
Refer
2/8/24  
Refer
2/20/24  
Report Pass
3/13/24  
Engrossed
4/10/24  
Refer
4/11/24  
Refer
4/24/24  
Report Pass
4/30/24  
Enrolled
5/26/24  
Chaptered
7/1/24  

Caption

INS-CONTINUOUS GLUCOSE MONITOR

Impact

The bill's provisions will modify the Illinois Insurance Code, specifically targeting coverage for CGMs and ensuring that insurers cannot impose deductibles or co-payments for CGM coverage starting from January 1, 2026. This change is expected to significantly lower the financial barriers for diabetic patients managing their condition, thereby improving health outcomes. Additionally, the legislation directs the Department to establish rules governing access to CGM coverage, ensuring guidelines match medical necessity criteria while simplifying the authorization process for both patients and healthcare providers.

Summary

SB3414 is a legislative act aimed at enhancing coverage for continuous glucose monitors (CGMs) for individuals diagnosed with diabetes mellitus. The bill mandates that both group and individual health insurance policies provide coverage for medically necessary CGMs starting from January 1, 2024. Importantly, once prescribed, individuals are no longer required to acquire prior authorization for the device. This legislation directly addresses the needs of those requiring comprehensive diabetes care, ensuring consistent access to essential monitoring tools.

Sentiment

The overall sentiment around SB3414 appears to be positive, particularly within diabetes advocacy groups and healthcare providers who support improved access to diabetes management tools. They view the bill as a critical step towards reducing healthcare barriers for diabetic patients. However, it may also draw concerns from insurance companies regarding cost implications and long-term financial impacts on healthcare plans, adding a layer of complexity to discussions about healthcare funding and resource allocation.

Contention

Despite the supportive sentiment, there is contention regarding the potential for increased healthcare costs as well as debates on how insurance companies will implement the terms of the bill. Critics may argue that the requirements around CGM prescriptions could create excessive demands on medical providers, while ensuring adequate training and follow-up for patients could divert resources from other healthcare necessities. The balance between encouraging CGM usage while controlling costs will likely remain a debated topic among stakeholders.

Companion Bills

No companion bills found.

Similar Bills

HI SB2030

Relating To Prescription Drugs.

NJ A3692

Requires physicians and other prescribers to obtain electronic or written consent for certain medications with "black box warnings."

NJ S150

Requires physicians and other prescribers to obtain electronic or written consent for certain medications with "black box warnings."

NJ S326

Requires physicians and other prescribers to obtain electronic or written consent for certain medications with "black box warnings."

AZ SB1164

Pharmacy benefits; coverage

DE HB140

An Act To Amend Title 16 Of The Delaware Code Relating To End Of Life Options.

DE HB140

An Act To Amend Title 16 Of The Delaware Code Relating To End Of Life Options.

NH HB1283

Relative to end of life options.